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Abstract
Background: Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with a strong genetic
component. The skewed prevalence toward males and evidence suggestive of linkage to the X chromosome in
some studies suggest the presence of X-linked susceptibility genes in people with ASD.
Methods: We analyzed genome-wide association study (GWAS) data on the X chromosome in three independent
autism GWAS data sets: two family data sets and one case-control data set. We performed meta- and joint analyses
on the combined family and case-control data sets. In addition to the meta- and joint analyses, we performed
replication analysis by using the two family data sets as a discovery data set and the case-control data set as a
validation data set.
Results: One SNP, rs17321050, in the transducin b-like 1X-linked (TBL1X) gene [OMIM:300196] showed
chromosome-wide significance in the meta-analysis (P value = 4.86 × 10
-6) and joint analysis (P value = 4.53 × 10
-6)
in males. The SNP was also close to the replication threshold of 0.0025 in the discovery data set (P = 5.89 × 10
-3)
and passed the replication threshold in the validation data set (P = 2.56 × 10
-4). Two other SNPs in the same gene
in linkage disequilibrium with rs17321050 also showed significance close to the chromosome-wide threshold in the
meta-analysis.
Conclusions: TBL1X is in the Wnt signaling pathway, which has previously been implicated as having a role in
autism. Deletions in the Xp22.2 to Xp22.3 region containing TBL1X and surrounding genes are associated with
several genetic syndromes that include intellectual disability and autistic features. Our results, based on meta-
analysis, joint analysis and replication analysis, suggest that TBL1X may play a role in ASD risk.
Background
Autism spectrum disorder (ASD) is a complex disorder
of neurodevelopmental origin which is characterized by
a well-established set of social, communicative and
behavioral impairments [1]. These impairments confer a
significant burden on individuals with ASD and their
families. This burden, in conjunction with a high ASD
prevalence (about 1 in 100 children ages 3 to 17 years
in the United States) [2], has spurred aggressive efforts
to identify ASD risk genes. Often reported but poorly
understood clinical phenomena with implications for
gene discovery efforts in ASD is the high male:female
ratio. Although this finding strongly suggests an etiolo-
gical role for the sex chromosomes [3,4], there has been
limited success in understanding the role of the sex
chromosomes associated with ASD risk.
Genome-wide linkage studies have implicated regions
on the X chromosome [5,6], and identification of struc-
tural variants in genes such as neuroligin 4, X-linked
(NLGN4X) demonstrate the potential role of X-linked
genes in autism [7]. Despite these results, gene-mapping
studies have focused on the autosomes, perhaps owing
* Correspondence: emartin1@med.miami.edu
1Hussman Institute for Human Genomics, Miller School of Medicine,
University of Miami, PO Box 019132 (M-860), Miami, FL 33101, USA
Full list of author information is available at the end of the article
Chung et al. Molecular Autism 2011, 2:18
http://www.molecularautism.com/content/2/1/18
© 2011 Chung et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.in part to the analytical difficulty of studying the X
chromosome in complex diseases. Taking advantage of
statistical methods specifically developed for this chal-
lenge [8], we investigated the X chromosome on a chro-
mosome-wide level in three recently completed
genome-wide association study (GWAS) data sets [9,10].
Herein we report our analysis of chromosome-wide
data on the X chromosome for association with ASD in
t w oi n d e p e n d e n tf a m i l y - b a s e ds a m p l e sa sw e l la si na
third independent sample of unrelated cases and con-
trols. We conducted meta-analysis and a novel approach
to joint analysis in the combined family and case-control
samples. We also combined the two family samples as a
discovery data set and used the case-control samples as
a validation data set and performed comprehensive ana-
lysis in the discovery and validation data sets to establish
replication. Furthermore, we investigated whether there
are SNPs in previously reported candidate genes for
ASD that show replication among the discovery, valida-
tion and joint data sets.
Subjects and methods
Study samples
Three data sets were used in this study. A total of 894
ASD families (3,128 individuals) ascertained by three
clinical groups at the John P. Hussman Institute for
Human Genomics (HIHG; Miami, FL, USA), the Uni-
versity of South Carolina (Columbia, SC, USA) and the
Vanderbilt Center for Human Genetics Research
(CHGR; Vanderbilt University, Nashville, TN, USA),
denoted collectively as HIHG/CHGR, were included in
this study. We combined this data set with a second
GWAS data set obtained from the Autism Genetic
Resource Exchange (AGRE). The full AGRE data set is
publicly available and comprises families with ASD.
There were 939 ASD families (4,495 individuals)
included in the AGRE GWAS. The third data set was
from the Autism Case-Control (ACC) cohort study con-
ducted at the Children’s Hospital of Philadelphia
(CHOP) [9]. The ACC cohort data were collected from
multiple sites across the United States, including CHOP.
The ACC controls had no history of ASD and were of
self-reported Caucasian ancestry. The data set consisted
of a total of 1,204 cases and 6,472 controls. Detailed
diagnostic criteria for the HIHG/CHGR data set can be
found in the study by Ma et al.[ 1 0 ] ,t h o s ef o rt h e
AGRE data set can be found on the AGRE website
(http://www.agre.org/) and those for the ACC data set
can be found in the study by Wang et al.[ 9 ] .I nb r i e f ,
the core inclusion criteria for the HIHG/CHGR data set
included (1) chronological age between 3 and 21 years
of age, (2) a presumptive clinical diagnosis of ASD and
(3) expert clinical determination of an ASD diagnosis
based on Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
[1] criteria and supported by the Autism Diagnostic
Interview-Revised (ADI-R) in the majority of cases and
all available clinical information. For AGRE, families
with one or more individuals diagnosed with ASD
(based on DSM-IV-TR and ADI-R) were selected. For
ACC, individuals with positive ADI/ADI-R or ADOS, or
both, were included. Detailed statistics for subpheno-
types such as autism, ASD and mean IQ for the data
sets can be found in Additional file 1.
Molecular methods
The HIHG/CHGR data set was genotyped in the geno-
typing core at the Center for Genome Technology at
HIHG. Samples passing sample quality checks were gen-
otyped using the Infinium Human1M version 1 Bead-
Chip Kit (Illumina Inc, San Diego, CA, USA), which
contains 1,072,820 SNPs (of which 36,377 loci are on
the X chromosome). The samples were processed in
batches of 48 according to Illumina procedures for pro-
cessing of the Infinium II assay. The above protocol was
automated using the Freedom EVO robotic system
(Tecan Group Ltd, Männedorf, Switzerland) to further
enhance the efficiency and consistency of the assay. A
common quality control (QC) DNA sample was
repeated during each run to ensure the reproducibility
of results between runs. Dataw e r ee x t r a c t e db yu s i n g
Illumina BeadStudio software from data files created by
the Illumina BeadArray Reader. Samples and SNPs with
call rates below 95% were excluded from analysis, and
an Illumina GenCall Data Analysis software cutoff score
of 0.15 was used for all Infinium II products (Illumina
Inc) [10]. The AGRE and ACC samples were genotyped
using the Illumina HumanHap550 Genotyping BeadChip
SNP genotyping array, which has 13,837 X-chromosome
SNPs from among a total of 555,175 SNPs. A more
detailed description of genotyping procedures used to
analyze the AGRE and ACC samples can be found in
the study by Wang et al. [9].
Sample quality control
In the HIHG/CHGR and AGRE data sets, individuals’
sex was determined on the basis of the X-chromosome
SNPs. Genome-wide identity by descent estimates were
used to test for relatedness between samples to detect
other sample errors. Families with a genome-wide Men-
delian error rate greater than 2% across SNPs were also
excluded from the analysis. These procedures were per-
formed using the PLINK software [11].
EIGENSTRAT [12] was used to identify population
stratification and remove outliers. We performed
EIGENSTRAT on autosomes of the parents in the
HIHG/CHGR and AGRE data sets. Families that had
individuals with eigenvectors in the first four principal
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mean were considered outliers and were removed from
the data. Only families of Caucasian descent (based on
self-report) passed the outlier standard. Families from
other racial groups, such as African-Americans and
Asian-Americans were removed as outliers. Similar pro-
cedures for sample QC were performed on the ACC
data set from CHOP [9].
SNP quality control
We used PLINK software to remove from the HIHG/
CHGR and AGRE data sets SNPs with Mendelian error
rates greater than 4% and P values less than 10
-4 for the
Hardy-Weinberg Equilibrium tests. SNPs with minor
allele frequency less than 0.01 were also excluded, since
the power to detect association with such rare variants
was low in this sample.
We identified several SNPs with significantly different
rates of missing genotypes in males and females where
the missing data are non-random with respect to geno-
type. Since the prevalence of ASD is higher in males
than in females, the difference in missing genotype rates
between males and females and genotype-specific miss-
ingness can change allele frequencies between indivi-
duals with ASD versus those without ASD, which can
lead to spurious association results. Therefore, to reduce
the effect of informative missingness, we excluded mar-
kers with a missing genotype rate more than 2.5% in
males or females.
In general, males are hemizygous for the X chromo-
some, except for three homologous regions shared by
the X and Y chromosomes. Markers in the two telo-
meric pseudoautosomal regions (PAR1 and PAR2) were
treated as autosomal markers in the QC and analysis. A
third region of XY homology, Xq21.3 and Yp11.1, as
well as several other smaller segments [13], differs from
t h eP A R si nt h a tt h eXa n dYc h r o m o s o m e sd on o t
recombine. This can result in different allele frequencies
in these regions on the X and Y chromosomes, which
can lead to spurious results in association tests. There-
f o r e ,S N P si nt h i sr e g i o na n dt h o s es h o w i n gm o r et h a n
1% male heterozygotes were removed from our analysis.
Male heterozygotes in the remaining SNPs may have
b e e nd u et oe r r o r si ng e n o t y p ec a l l s ,t h u st h e i rg e n o -
types at that SNP were set to be missing.
Statistical analysis
For joint analysis of the pooled data sets (HIHG/CHGR,
AGRE and ACC), we used a modified version of X-APL
[8] that combines family and unrelated case-control data
[14]. Briefly, unrelated cases and controls were inte-
grated into the family-based framework by treating each
as a proband from a family triad with missing parental
data. In this way, they contributed indirectly to
inferences regarding missing parental data across the
sample and directly to inferences about ASD-SNP asso-
ciations. We found that the joint analysis resulted in a
high inflation factor (l > 1.6) based on the genomic
control (GC) approach [15]. The high inflation factor
could be due to the batch effect in the ACC data set, as
discussed below, but it also could be due to the fact that
QC analyses of population stratification for family and
case-control data were performed separately at two sites
(HIHG/CHGR and CHOP). Applying the GC approach
to the joint analysis results had a drastic effect on the
power to detect true positives. Therefore, we performed
stratified analysis by grouping HIHG/CHGR and AGRE
into one cluster and ACC into the other cluster in the
joint analysis. Allele frequencies were inferred individu-
ally in the two clusters, and an X-APL statistic was cal-
culated for each cluster. The statistics from the two
clusters were summed to form a final statistic, and var-
iance for the statistic was estimated jointly on the basis
of the data derived from the two clusters. We also used
a meta-analysis approach comprising steps similar to
those described by Wang et al. [9] to combine the X-
APL statistics from the HIHG/CHGR and AGRE
cohorts with the GC-corrected statistics from the ACC
sample.
For the replication analysis, association tests in the
individual data sets were conducted using the PLINK
software [11] for case-control analysis based on allele-
based c
2 tests and X-APL in families [8]. APL [16] and
allele-based c
2 tests for autosomes using the PLINK
software were performed to detect SNPs in PAR1 and
PAR2. Unaffected siblings were also included in family-
based analyses, as they helped us infer missing parental
genotypes. The analysis of the ACC data set had an
inflation factor (that is, l value [15]) of 1.12, which may
reflect a batch effect, since cases and controls were gen-
otyped in separate batches as described in the supple-
ment section of the study by Wang et al.[ 9 ] .W e
applied the GC approach to the results for the case-con-
trol analysis as suggested by Wang et al. [9] to correct
for the batch effect. We used the combined family data
set (HIHG/CHGR and AGRE) as our discovery data set
and the case-control data set (ACC) as the validation
data set. We performed individual analyses of the dis-
covery and validation data sets and investigated whether
the results were replicated in both data sets.
We also investigated whether there were significant
signals in candidate genes identified in previous studies
for interesting, albeit not chromosome-wide, significant
SNPs. SNPs with P values less than 0.05 in the discov-
ery, validation and joint analyses as well as in candidate
genes found in the literature were considered significant.
A total of 21 candidate genes for ASD on the X chro-
mosome reported in the Autism Genetic Database [17]
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given in Additional file 2. On the basis of considering
only 776 SNPs in the 21 candidate genes from among
the 10,820 overlapping SNPs in the discovery, validation
and joint data sets, we expected that the chance of a
SNP being significant in the discovery, validation and
joint data sets and in a candidate gene would be small.
A diagram depicting the analytical strategy is shown in
Additional file 3.
To investigate whether there are sex-specific effects in
ASD, we also performed case-control tests for males
and females separately. For family-based analysis, we
performed sex-specific tests proposed by Chung et al.
[8] by calculating the transmission of alleles from par-
ents to affected males and affected females separately.
Because cases and controls were integrated into the
family-based framework, male- and female-specific tests
were calculated similarly in the joint analysis based on
the modified version of X-APL.
Current imputation methods have been developed
mainly for unrelated samples, which were not suitable
for analysis of the HIHG/CHGR and AGRE data sets.
Recently, the genotype imputation method BEAGLE
[18] was proposed to study triads and unrelated indivi-
duals; however, this method is restricted to autosomal
SNPs and family triads. Given these practical restrictions
and the fact that there was still good coverage with the
overlapping SNPs (10,820 SNPs), we analyzed only SNPs
common to the three data sets for the meta- and joint
analyses.
The use of a traditional Bonferroni correction for mul-
tiple testing was conservative because of linkage disequi-
librium (LD) among markers. We used the simpleM
method based on principal component analysis to
choose the “effective number” of independent tests [19].
The P values corrected using the simpleM method were
similar to those corrected by the permutation procedure
for multiple testing [19]. The effective number for the
HIHG/CHGR data set was about 11,500 and that for
the AGRE, ACC and joint data sets was about 8,000.
With the chromosome-wide correction set at 0.05 based
on the simpleM method, the SNP-wise significance
levels were approximately 4.3 × 10
-6 for the HIHG/
CHGR analysis and approximately 6.25 × 10
-6 for the
AGRE, ACC and joint analysis. For replication analyses,
s i n c et h ed i s c o v e r yd a t as e t( H I H G / C H G Ra n dA G R E )
and validation data set (ACC) were independent, we
considered a replication threshold of

6.25 × 10−6 =0 . 0 0 2 5. The results were replicated if
their P values were less than 0.0025 in both the discov-
ery and validation data sets. This assures a chromo-
s o m e - w i d et y p eIe r r o rr a t eo fn om o r et h a n0 . 0 5f o r
replicated results. Table 1 summarizes the significance
thresholds for the meta-analysis, joint analysis, replica-
tion analysis and candidate gene analysis.
Results
Quality control results
The final data sets included 2,557 samples from 735 ASD
families in the HIHG/CHGR data set, 3,289 samples from
721 ASD families in the AGRE data set and 1,204 cases
and 6,472 controls from the ACC data set. The HIHG/
CHGR data set had 620 singleton families (parent-child
trio) and 115 multiplex families (more than one affected
sibling). The AGRE data set had 138 singleton families
and 583 multiplex families. After applying the QC filters,
the following data sets remained: 24,712 X-chromosome
SNPs (including 356 SNPs in PAR1 and PAR2) remained
in the HIHG/CHGR data set, with an average call rate of
99.75%; 11,164 X-chromosome SNPs (including 15 SNPs
in PAR1 and PAR2) remained in the AGRE data set, with
an average call rate of 99.62%; and 11,098 X-chromosome
SNPs (including 15 SNPs in PAR1 and PAR2) remained in
the ACC data set, with an average call rate of 99.61%. In
the three data sets, there were 10,820 overlapping X-chro-
mosome SNPs for the meta- and joint analyses. The ratios
of affected males to affected females in the HIHG/CHGR,
AGRE and ACC data sets were 4.97, 3.82 and 4.6, respec-
tively. The ratio of male controls to female controls in the
ACC data set was 1.1. The detailed QC results from differ-
ent procedures for samples and genotypes are given in
Additional file 4.
Meta-analysis and joint analysis
F i g u r e1s h o w st h ep l o to ft h eP values for the overall,
male-specific and female-specific tests based on the
meta-analysis. The SNP rs17321050 in the transducin b-
like 1X-linked (TBL1X) gene shows the chromosome-
wide significance with a P v a l u eo f4 . 8 6×1 0
-6 for the
male test. The joint analysis also identified the same
SNP, rs17321050, with a chromosome-wide statistically
significant P =4 . 5 3×1 0
-6 for the male test. Notably,
the P value for this SNP also was very close to the
Table 1 Thresholds for significance in meta- and joint analyses, replication analysis and candidate gene analysis
Analysis type Threshold for significance
Meta- or joint analysis P < 6.25 × 10
-6 in either the meta- or joint analysis
Replication analysis P < 0.0025 in both discovery and validation analyses
Candidate gene analysis P < 0.05 in discovery, validation and joint analyses, and the SNP is in a candidate gene for autism
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the replication threshold in the validation data set, as
shown in Table 2. We identified two other SNPs
(rs5934665 and rs2188766) in the TBL1X gene that were
close to the chromosome-wide significance in the meta-
analysis for males (Table 2). These two SNPs were also
close to the replication threshold of 0.0025 in both the dis-
covery and validation data sets. These two SNPs,
rs5934665 and rs2188766, showed evidence of LD in the
joint data set with rs17321050 at r
2 =0 . 6 4a n dr
2 =0 . 6 5 ,
respectively (Additional file 5). Figure 2 shows the P values
for males and the LD structures of the SNPs in the region.
We show the allele and genotype frequencies for the three
markers in parents, cases and unrelated controls in Addi-
tional file 6. We also performed a haplotype test for males
for the three markers, but the association was not as sig-
nificant as the single-marker tests (P = 0.001 for the global
test in the meta-analysis). As shown in Table 2 the three
SNPs were not significant for females.
Replication analysis
Individually, no SNPs met the stringent threshold for
multiple testing in either the discovery or validation
data sets, nor did any SNPs pass the replication thresh-
old in both the discovery and validation data sets.
Candidate gene analysis
The results for significant SNPs in candidate genes are
shown in Table 3. We identified SNP rs721699 in the
Duchenne muscular dystrophy gene Dystrophin (DMD)
[OMIM:300377] in the overall test and SNPs rs9887672,
rs10218388 and rs5962575 in the IL-1 receptor acces-
sory protein-like 2 (IL1RAPL2) gene [OMIM:300277] in
the male test. The allele and genotype frequencies of the
SNPs in parents, cases and unrelated controls are given
in Additional file 6.
Discussion
Our study represents the largest chromosome-wide
study of the X chromosome in association with ASD.
Combining three independent GWAS studies allowed us
to thoroughly evaluate the X chromosome using meta-
and joint analyses in the pooled sample to improve our
study’s power to detect true-positives. Also, the replica-
tion and candidate gene analyses were used to further
filter out false-positives. We found one intronic SNP,
rs17321050, in TBL1X that demonstrated chromosome-
wide evidence of association in the meta- and joint ana-
lyses, strongly supporting TBL1X as a risk factor for
ASD. This finding was further supported by the replica-
tion analysis. Our estimates of the odds ratios for
rs17321050 in TBL1X for males, based on the major
allele as the reference, are 0.85 (95% confidence interval
(95% CI) = 0.74 to 0.99) in the discovery data set and
0.74 (95% CI = 0.63 to 0.86) in the validation data set.
Though modest, these effects were consistent across
samples and similar to effect sizes seen for other signifi-
cant regions in other recent GWASs of complex
Figure 1 Plot for -log10 (P values) for the overall, male-specific and female-specific tests based on the meta-analyses. The red line
indicates the threshold for chromosome-wide multiple testing correction.
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ratios is that these associations reflect rare variants
(structural variations or copy number variants (CNVs))
with very strong effects on ASD in LD with the signifi-
cant SNPs. Follow-up sequencing might be warranted to
identify the rare variants. Alternatively, the modest odds
ratios might simply be due to the fact that the autism
loci in LD with the SNPs have modest effects on the
disorder. Moreover, the major allele in rs17321050,
which is the positively associated allele, may be in LD
with the risk alleles in the autism loci. Also, the SNP
could have an unknown regulatory effect, as it is intro-
nic with no predicted function. We performed a power
study based on the sample sizes and show the power
curves in Additional file 7. The power study suggests
that, given the sample size and relative risk greater than
1.3, the test has more than 70% power to detect the true
signal when the ASD allele frequency is greater than 0.3.
The power study further demonstrates that the study
design has the power to detect markers with modest
effects on ASD.
The peak result in TBL1X is particularly interesting
because TBL1X is in the Wnt signaling pathway [KEGG
pathway ID:hsa04310]. The Wnt family of proteins is a
highly conserved group of genes that are key mediators
of cell-cell signaling during embryogenesis and play an
essential role in the generation of normal embryos.
Many WNT receptors are expressed during develop-
ment and in the adult central nervous system. Previously
published experiments have also suggested that the Wnt
signaling pathway may function differently in brain
regions based on expression analysis in mouse brain
[21]. TBL1X and its family member transducin b-like 1
X-linked receptor 1 (TBL1XR1) [OMIM:608628] have
been shown to interact with b-catenin and bind to the
promoter of Wnt target genes induced by Wnt signaling
[22]. Engrailed 2 (EN2) [OMIM:131310], a Wnt target
gene [23], has been associated with autism in several
Table 2 Results for the SNPs that survived chromosome-wide multiple testing in the meta- and joint analyses and for
the two neighboring significant SNPs
Marker Map position (bp) Minor/major allele MAF
a Discovery Validation Meta Joint Test Gene
rs5934665 9,570,450 G/A 0.433 2.87 × 10
-3 1.87 × 10
-3 1.77 × 10
-5 3.00 × 10
-5 Male TBL1X
rs5934665 9,570,450 G/A 0.449 2.46 × 10
-1 3.24 × 10
-1 8.59 × 10
-1 4.67 × 10
-1 Female TBL1X
rs17321050 9,573,099 G/T 0.335 5.89 × 10
-3 2.56 × 10
-4 4.86 × 10
-6 4.53 × 10
-6 Male TBL1X
rs17321050 9,573,099 G/T 0.359 1.99 × 10
-1 5.22 × 10
-1 6.15 × 10
-1 3.85 × 10
-1 Female TBL1X
rs2188766 9,574,739 C/T 0.432 4.33 × 10
-3 4.42 × 10
-4 7.76 × 10
-6 2.00 × 10
-5 Male TBL1X
rs2188766 9,574,739 C/T 0.451 2.34 × 10
-1 3.80 × 10
-1 7.86 × 10
-1 4.21 × 10
-1 Female TBL1X
aMinor allele frequency (MAF) estimated on the basis of the discovery data set. TBL1X = transducin b-like 1X-linked gene.
Figure 2 Plot for the P values and LD structures for SNPs surrounding the three significant SNPs in TBL1X. The plot was generated using
SNAP software [45]. LD = linkage disequilibrium; TBL1X = transducin b-like 1X-linked gene.
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mammary tumor virus integration site family, member
2) [OMIM:147870] is a candidate gene for autism [28].
Therefore, TBL1X plays a role in pathways that may be
critical to the etiology of autism and is an excellent can-
didate gene.
The region containing TBL1X carries CNVs that have
been associated with a diverse range of neurodevelop-
mental phenotypes. Multiple studies have shown that
deletions in the Xp22.2 to Xp22.3 distal region that con-
tain NLGN4 and TBL1X are associated with autism.
Researchers in one study found deletions encompassing
the Xp22.3 region in three autistic females [29]. Investi-
gators in another study identified a 5.5-Mb deletion in
the Xp22.2 to Xp22.3 region in a female who had aut-
ism, moderate mental retardation and some dysmorphic
features [30]. A familial deletion in the Xp22.2 to
Xp22.3 region has been found to be associated with a
variable phenotype, including autism, in female carriers
[31]. TBL1X is about 5 Mb from the NLGN4 gene
[OMIM:300427]. Researchers in several studies have
suggested that deletions or point mutations in NLGN4
are associated with autism [32,33]. Furthermore, TBL1X
is partially or completely deleted in patients with the
ocular albinism with late-onset sensorineural deafness
(OASD) gene [OMIM:300650] carrying Xp22.3-terminal
deletions. Given these findings, we used PennCNV [34]
to identify possible CNVs in the Xp22.2 to Xp22.3
region in our data set. Only one affected female sibling
carried a single-copy duplication, with a size of 10.26
kb, in the TBL1X gene region. However, the lack of
CNV identification in the TBL1X region might be due
to the limitation of CNV identification algorithms based
on GWAS data [35].
The association at TBL1X is even more intriguing,
given that it is seen only in the male-only analysis. The
P values of the female-specific tests for the three signifi-
cant markers given in Table 2 were all greater than 0.1
in the individual, joint and meta-analyses. This suggests
the possibility of a recessive effect at this locus; however,
analysis of affected females with a recessive model did
not improve the statistical significance. Alternatively, the
lack of significance in females could be explained by
skewed, allele-specific X-chromosome inactivation,
which has been suggested previously in autism [36], or
simply by low power in the female subset due to its
relatively small sample size compared to males, as
shown in Additional file 4.
The TBL1X gene has not been reported in other associa-
tion studies of ASD. This might be due to the limited sam-
ple sizes, as we have shown that the odds ratios of the
SNPs are modest. Wang et al. [9] also analyzed the X-
chromosome markers for ASD using the AGRE and ACC
data sets for replication analysis and meta-analysis. The
markers in TBL1X did not pass the meta-analysis thresh-
old of 1 × 10
-4 in their studies. We increased the sample
size by including the HIHG/CHGR data set as well as the
AGRE and ACC data sets in the meta- and joint analyses,
which increased the power of our association studies.
We also found that two candidate genes, DMD and
IL1RAPL2, were significantly associated with the discov-
ery and validation data sets based on ap r i o r ihypotheses
at previously identified candidate genes. The finding of a
significant SNP (rs721699 in the DMD gene) warrants
mention in light of recent findings in which exon dupli-
cations in the DMD gene were found to give rise to an
autism phenotype [37]. The results reported by Pagna-
menta et al. [38] support previous work by Hendriksen
and Vles [39] in showing an increased rate, relative to the
general population, of autism features in individuals with
DMD. Although this finding is most likely a result of LD
with functional variants in DMD, it adds to the growing
body of work suggesting that autism may co-occur with
other neurological conditions. Moreover, investigators in
a recent study found a hemizygous deletion in the DMD
gene in a male who had been diagnosed with ASD and
later with muscle weakness [40]. Researchers in other
studies have also suggested that IL1RAPL1, which is clo-
sely related to the IL1RAPL2 gene, identified in this
study, is associated with autism [41,42].
Wang et al. [9] found that the three markers
rs11798405, rs5972577 and rs6646569 on the X chro-
mosome showedstatistically significant association with
ASD, with P values less than 10
-5 based on meta-analy-
sis of individual P values for AGRE and ACC. However,
we observed significantly higher missing genotype rates
for SNPs rs5972577 and rs6646569 in males than in
females consistently across the HIHG/CHGR, AGRE
Table 3 Results for SNPs with replication and meta- and joint analysis P values < 0.05 and within candidate genes or
regions
Marker Map position (bp) Minor/major allele MAF
a Discovery Validation Meta Joint Test Gene
rs721699 32,468,253 T/C 0.384 7.45 × 10
-3 4.72 × 10
-2 9.57 × 10
-4 5.70 × 10
-4 Overall DMD
rs9887672 104,882,811 T/C 0.103 2.17 × 10
-2 1.53 × 10
-3 1.28 × 10
-4 1.20 × 10
-3 Male IL1RAPL2
rs10218388 104,875,605 C/T 0.107 3.08 × 10
-2 2.64 × 10
-3 2.94 × 10
-4 2.5 × 10
-4 Male IL1RAPL2
rs5962575 104,868,160 C/T 0.107 3.44 × 10
-2 2.19 × 10
-3 2.86 × 10
-4 2.30 × 10
-4 Male IL1RAPL2
aMinor allele frequency (MAF) estimated on the basis of the discovery data set. DMD = Dystrophin Duchenne muscular dystrophy gene; IL1RAPL2 = IL-1 receptor
accessory protein-like 2 gene.
Chung et al. Molecular Autism 2011, 2:18
http://www.molecularautism.com/content/2/1/18
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these higher missing genotype rates can cause spurious
association results. The problem of differential missing-
ness between the sexes can be eliminated in sex-
matched case-control studies. However, for family-based
studies or case-control studies not matched on sex, the
patterns of missing data between the sexes should be
carefully examined, especially for sex-linked chromo-
somes. In Additional file 9, we show that the missing
g e n o t y p er a t e sf o rt h em a r k e r si nT a b l e2a r ev e r yl o w ,
which suggests that the statistical significance for these
markers are not a result of the informative missingness.
The proportion of markers (for example, 4.3% in the
HIHG data set with P values less than 0.05 for the miss-
ingness tests between males and females) on the X chro-
mosome that showed this differential missingness is
what we expected by chance alone, which suggests that
there is no systemic defect in the genotype calling algo-
rithm for the X chromosome. The differential missing-
ness between the sexes may be due to sequence
homology or CNVs, which can introduce outliers into
the intensity plots [43]. We set the threshold for missing
genotypes at 2.5% for either males or females for each
SNP in our QC procedure to minimize the effects of
this problem. This resulted in the removal of SNPs
rs5972577 and rs6646569 from our analyses. We also
found that reclustering the samples without reference
samples before genotype calling reduced the effect of
the nonrandom and allele-specific missingness on asso-
ciation tests. For example, rs11798405 did not show sig-
nificant results (P value greater than 0.05) in our
reclustered AGRE samples, though it had a P value =
0.0067 in the study be Wang et al.[ 9 ] .I na n o t h e rA S D
study [44], none of the markers on the X chromosome
were reported to be significant. This could be due to the
smaller sample size used in the study (2,394 probands)
than we had in our study (3,503 affected individuals).
Conclusion
This study has identified a gene associated with ASD,
TBL1X. This gene showed modest but consistent effects in
a family-based discovery data set and an independent
case-control validation data set comprising males. Com-
bined functional evidence with respect to pathways and
prior evidence of this region involved with variable pheno-
types suggests that further studies, such as fine-mapping
of the gene, could identify ASD-associated regulatory var-
iants, protein-altering rare variants and CNVs.
Additional material
Additional file 1: Detailed statistics for subphenotypes of the data
sets. Additional file 1 contains detailed statistics for the subphenotype
information for the John P Hussman Institute for Human Genomics/
Center for Human Genetics Research (HIHG/CHGR) and Autism Genetic
Resource Exchange (AGRE) data sets.
Additional file 2: A list of candidate genes for ASD used in the
candidate gene analysis. Additional file 2 is a list of the 21 candidate
genes for autism spectrum disorder used to calculate statistical
significance in candidate genes on the X chromosome.
Additional file 3: Procedures for the statistical analyses. Additional
file 3 describes the procedures used in the three analyses (that is, joint
analysis, meta-analysis and replication analysis).
Additional file 4: Quality control steps. Additional file 4 lists the
detailed statistics for the samples passing the quality control (QC) steps.
Additional file 5: LD pattern among SNPs in the TBL1X gene based
on unrelated individuals. Additional file 4 gives the linkage
disequilibrium (LD) measures (r
2) for the significant SNPs and
surrounding SNPs in the transducin b-like 1X-linked (TBL1X) gene.
Additional file 6: Allele and genotype frequencies of parents, cases
and controls for significant SNPs. Additional file 6 shows the allele and
genotype frequencies of parents, cases and controls for the significant
SNPs reported in Tables 2 and 3.
Additional file 7: Power study results. Additional file 7 shows the
power curves under different relative risks, minor allele frequencies and
disease models, given the sample sizes in our study.
Additional file 8: Differences in missing data between males and
females in the study. Additional file 8 describes the problem of
differences in missing genotype data, with statistics and figures showing
the problem.
Additional file 9: Missing genotype rates for the markers
rs5934665, rs17321050 and rs2188766. Additional file 9 lists the
missing genotype rates for males, females and overall samples for the
significant markers in TBL1X.
Abbreviations
IL: interleukin; kb: kilobase; Mb: megabase; SNP: single-nucleotide
polymorphism.
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